Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening

Area of Science:

• Medical Genetics
• Public Health
• Neonatal Medicine

Background:

• Neonatal screening programs are crucial for early detection of treatable congenital disorders.
• China has made significant strides in expanding its neonatal screening initiatives in recent years.
• Understanding the current prevalence of key conditions like hyperphenylalaninemia and congenital hypothyroidism is vital for public health planning.

Purpose of the Study:

• To assess the status and scope of neonatal screening in China.
• To determine the incidence rates of hyperphenylalaninemia (HPA) and congenital hypothyroidism (CH) in the screened population.
• To evaluate the progress and identify challenges in national neonatal screening coverage.

Main Methods:

• Analysis of national neonatal screening data from 2000 to 2007.
• Calculation of prevalence rates for HPA and CH based on screened newborn populations.
• Review of screening advancements, including the introduction of tandem mass spectrometry in Shanghai.

Main Results:

• Over 17.9 million newborns were screened for HPA, with a prevalence of 1:11,763.
• Over 18.2 million newborns were screened for CH, with a prevalence of 1:2050.
• A fivefold increase in the annual number of screened newborns was observed between 2000 and 2007. In Shanghai, tandem mass spectrometry identified inborn errors of metabolism at a prevalence of 1:5800.

Conclusions:

• Neonatal screening has developed rapidly in China, with significant increases in coverage and the introduction of advanced technologies.
• Hyperphenylalaninemia and congenital hypothyroidism are significant public health concerns requiring continued screening efforts.
• Expanding screening coverage nationwide, particularly in underserved regions, remains the primary challenge for effective public health implementation.